Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)

Affiliation auteurs!!!! Error affiliation !!!!
TitreEffect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)
Type de publicationJournal Article
Year of Publication2016
AuteursMamez A-C, Levy V., Chevallier P., Blaise D., Vigouroux S., Xhaard A., Fegueux N., Contentin N., Beguin Y., Ifrah N., Bulabois C-E, Suarez F., Yakoub-Agha I., Turlure P., Deconink E., Lamy T., Cahn J.Y, huynh A., Maury S., Fornecker L.M, Ouzegdouh M., Bay J-O, Guillerm G., Maillard N., Michallet M., Malfuson J-V, Bourhis J-H, Rialland F., Oumedaly R., Jubert C., Leblond V., Boubaya M., Mohty M., Nguyen S.
JournalBONE MARROW TRANSPLANTATION
Volume51
Pagination358-364
Date PublishedMAR
Type of ArticleArticle
ISSN0268-3369
Résumé

{Peripheral T-cell lymphoma carries a poor prognosis. To document a possible graft-versus-lymphoma effect in this setting, we evaluated the impact of immunomodulation in 63 patients with peripheral T-cell lymphoma who relapsed after allogeneic transplant in 27 SFGM-TC centers. Relapse occurred after a median of 2.8 months. Patients were then treated with non-immunologic strategies (chemotherapy, radiotherapy) and/or immune modulation (donor lymphocyte infusions (DLI) and/or discontinuation of immunosuppressive therapy). Median overall survival (OS) after relapse was 6.1 months (DLI group: 23.6 months, non-DLI group: 3.6 months). Among the 14 patients who received DLI, 9 responded and 2 had stable disease. Among the remaining 49 patients, a complete response accompanied by extensive chronic GvHD was achieved in two patients after tapering of immunosuppressive drugs. Thirty patients received radio-chemotherapy, with an overall response rate of 50%. In multivariate analysis, chronic GvHD (odds ratio: 11.25 (2.68-48.21)
DOI10.1038/bmt.2015.280